|
ZBTB26 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.50089957024124E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.88829959949055E-10 |
| Normal-vs-Stage2 |
3.1903999997418E-08 |
| Normal-vs-Stage3 |
2.88025159278504E-12 |
| Normal-vs-Stage4 |
2.99593683195098E-12 |
| Stage1-vs-Stage2 |
9.535600E-01 |
| Stage1-vs-Stage3 |
3.862100E-02 |
| Stage1-vs-Stage4 |
1.094090E-02 |
| Stage2-vs-Stage3 |
1.666780E-01 |
| Stage2-vs-Stage4 |
9.548100E-02 |
| Stage3-vs-Stage4 |
5.425000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.25309779114491E-11 |
| Normal-vs-AfricanAmerican |
2.19519999999918E-06 |
| Normal-vs-Asian |
1.80659998072485E-09 |
| Caucasian-vs-AfricanAmerican |
3.497800E-01 |
| Caucasian-vs-Asian |
8.239400E-01 |
| AfricanAmerican-vs-Asian |
4.940600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.9671042572611E-11 |
| Normal-vs-Female |
7.15310033427841E-11 |
| Male-vs-Female |
3.367000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.18869955282264E-10 |
| Normal-vs-Age(41-60Yrs) |
5.09290387640249E-11 |
| Normal-vs-Age(61-80Yrs) |
6.05915317919425E-12 |
| Normal-vs-Age(81-100Yrs) |
3.764900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.378200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.535900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.956600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.636000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.492200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.907000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.222000E-03 |
| Classical-VS-Follicular |
8.980000E-01 |
| Classical-VS-Other |
4.541600E-01 |
| Classical-VS-Normal |
4.39760006187839E-10 |
| Tall-VS-Follicular |
3.664400E-02 |
| Tall-VS-Other |
6.890400E-01 |
| Tall-VS-Normal |
4.69735361718904E-12 |
| Follicular-VS-Other |
5.718800E-01 |
| Follicular-VS-Normal |
1.70189973225376E-10 |
| Other-VS-Normal |
1.797540E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02640007604293E-10 |
| Normal-vs-N1 |
4.14950296345751E-11 |
| N0-vs-N1 |
1.995990E-01 |
|
|
